Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Hepatocell Carcinoma. 2015 Oct 9;2:151-7. doi: 10.2147/JHC.S75153. eCollection 2015.
Fibrolamellar carcinoma (FLC) is a variant of hepatocellular carcinoma (HCC), which comprises ∼1%-9% of all HCCs. Although FLC is a variant of HCC, it is distinct from HCC in that it most often affects younger patients (10-35 years of age) with no underlying liver disease. FLC often presents with vague abdominal pain, nausea, abdominal fullness, malaise, and weight loss. Surgery is the current mainstay of treatment for FLC and remains the only potentially curative option. While FLCs are considered less responsive to chemotherapy than their classic HCC counterparts, there have been suggestions that multimodality treatments may be effective, especially in advanced cases. Further research is necessary to determine effective systemic therapies as an adjunct to surgery for FLC.
纤维板层样肝细胞癌（FLC）是肝细胞癌（HCC）的一种变体，约占所有 HCC 的 1%-9%。尽管 FLC 是 HCC 的一种变体，但它与 HCC 不同，因为它通常影响没有潜在肝病的年轻患者（10-35 岁）。FLC 常表现为模糊的腹痛、恶心、腹胀、不适和体重减轻。手术是目前治疗 FLC 的主要方法，也是唯一潜在的治愈方法。虽然 FLC 对化疗的反应不如其经典 HCC 对应物敏感，但有研究表明，多模式治疗可能有效，尤其是在晚期病例中。需要进一步的研究来确定有效的系统治疗方法作为 FLC 手术的辅助治疗。
